Wells Fargo
AST.WS

Wells Fargo’s Asterias Biotherapeutics Inc. Warrants (expiring September 29, 2017) AST.WS Stock Holding History

Wells Fargo’s Portfolio AST.WS Stock Details AST.WS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-76
Closed – – 6732
2017
Q2 		$0 Buy
76
+20
+36% +$9 ﹤0.01% 6769
2017
Q1 		$0 Hold
56
– – ﹤0.01% 6792
2016
Q4 		$0 Buy
56
+4
+8% +$2 ﹤0.01% 6732
2016
Q3 		$0 Sell
52
-6
-10% -$2 ﹤0.01% 6644
2016
Q2 		$0 Buy
+58
New +$30 ﹤0.01% 6734

Wells Fargo's AST.WS Position: Q3 2017 in Review

Wells Fargo sold out of Asterias Biotherapeutics Inc. Warrants (expiring September 29, 2017) (AST.WS) in Q3 2017, closing a stake of 76 shares.

Wells Fargo first reported a position in AST.WS in Q2 2016 and held it in 5 quarters. The position peaked at $0 in Q2 2017. 3 funds tracked by Wall St. Rank hold AST.WS as of Q3 2017.

  • Wells Fargo reported no remaining Asterias Biotherapeutics Inc. Warrants (expiring September 29, 2017) position as of Q3 2017 after selling out during the quarter.
  • Wells Fargo sold 76 Asterias Biotherapeutics Inc. Warrants (expiring September 29, 2017) shares in Q3 2017.
  • Wells Fargo first reported a position in Asterias Biotherapeutics Inc. Warrants (expiring September 29, 2017) in Q2 2016 and held it in 5 quarters.
  • Wells Fargo's Asterias Biotherapeutics Inc. Warrants (expiring September 29, 2017) position peaked at $0 in Q2 2017.
  • 3 funds tracked by Wall St. Rank held Asterias Biotherapeutics Inc. Warrants (expiring September 29, 2017) as of Q3 2017.

Based on Wells Fargo's 13F filing for Q3 2017, filed 9 Nov 2017.